Physician- and Patient-based Barriers to NGS Testing
Recruiting
N/A
Interventional Study
Metastatic Prostate Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Male
- Study type
- Interventional
- Purpose
- Other
- Participants needed
- 256 (estimated)
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this study is to improve next-generation sequencing (NGS) testing rates at Johns Hopkins in patients with metastatic prostate cancer. Investigators believe by targeting two barriers, provider-level and patient-level, will improve the testing rate of NGS at Johns Hopkins.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* men diagnosed with metastatic prostate cancer
* seen by Johns Hopkins Medical Oncology as a new patient visit between January 1, 2025 and December 31, 2026
Exclusion Criteria:
\- Patients who have already had NGS testing performed.
Contacts